EGFR is overexpressed in approximately 80% of CRCs and correlates with increased propensity to metastasis and decreased patient survival [19, 22] and EGFR‐targeted therapeutic monoclonal antibodies, cetuximab and panitumumab, are approved for the treatment of metastatic disease [23]. This evidence concerns the gene EGFR and metastatic neoplasm.